INTRODUCTION
============

Chronic hepatitis B virus (HBV) infection might lead to a wide spectrum of liver injury ranging from chronic healthy HBsAg carrier to rapidly progressive decompensated liver cirrhosis. With advances in molecular biology technology, the role of HBV variants in the pathogenesis of such varied liver damage has been investigated; precore mutants of the HBV were first found in patients with severe liver disease after seroconversion to anti-HBe^[@b1-kjim-10-2-87-2]--[@b6-kjim-10-2-87-2]^ and later also in those with normal transaminase levels^[@b7-kjim-10-2-87-2]--[@b9-kjim-10-2-87-2]^; therefore, precore variant is no longer considered to be associated with the severity of chronic hepatitis B (CH-B).

Hepatic injury due to HBV is thought to be immune-mediated^[@b10-kjim-10-2-87-2]^. The HBcAg is the most probable immunological target of cytotoxic T cell (CTL)^[@b11-kjim-10-2-87-2]^. Studies on endogenously-processed viral peptides demonstrated that a peptide as small as 8 to 9 amino acids could be recognized by CTL^[@b12-kjim-10-2-87-2],[@b13-kjim-10-2-87-2]^. Thus, it could be supposed that if there is 'pressure' from CTL, one might expect to find a mutation of the amino acid sequence in a restricted segment of the core gene. The studies from Japan and Taiwan have shown the clustering of missense mutations in the core gene^[@b14-kjim-10-2-87-2],[@b15-kjim-10-2-87-2]^, though there were some differences of the major regions for mutation clustering between the two studies. These differences might originate from differing distributions of HLA antigens or from the varying amino acid sequences among HBV subtypes between the two countries^[@b15-kjim-10-2-87-2]^, and this proposal remains to be confirmed by more studies in different countries.

Korea is a hyperendemic area of HBV^[@b16-kjim-10-2-87-2]^. However, the role of HBV variants in the severity of liver damage in Korean patients with chronic HBV infection has not been assessed. To explore the phenomenon of clustering mutations in patients with chronic HBV infection and to elucidate the correlation between clustering mutation region of the core gene and the severity of liver damage, we analyzed the precore/core gene sequence of HBV in the sera from fifteen Korean patients with CH-B.

METHODS
=======

1.. Patients
------------

We analysed the HBV precore and core sequences in the sera obtained from fifteen patients (14 males and 1 female, mean age 30.0 years) with biopsy-proven CH-B. The patients were divided into two groups according to the pathological severity of CH-B; namely, group I consisted of 8 patients with chronic persistent hepatitis (CPH), and group II included 7 patients with chronic active hepatitis (CAH). Serologic markers for HBV (HBsAg and HBeAg/anti-HBe) were detected by commercially available radioimmunoassay kits (Ausria II and HBe Kit, respectively; Abbott laboratories, North Chicago, IL, USA).

2.. Extraction of DNA from Serum
--------------------------------

Serum (200--300*μ*l) obtained from each patient was incubated at 70°C for 3 hours in a mixture of proteinase K (100*μ*g/ml), 0.5% (wt/vol) SDS, 5mM EDTA, and 10 mM Tris-HCl, pH 8.0. The solution was subjected to phenol-chloroform extraction, and DNA was precipitated with ethanol.

3.. Amplification and Direct Sequencing of the Precore and Core Region of HBV
-----------------------------------------------------------------------------

To amplify a segment of HBV DNA that constitutes the entire precore and core region, we prepared a set of synthetic oligonucleotide primers according to the HBV sequence reported by Kim et al.^[@b17-kjim-10-2-87-2]^ : a sense primer (nt 1604--1623, 5′-CATGGAGACC ACCGTGAACG-3′) and a antisense primer (nt 2526--2547, 5′-GTG AGGAAAGGAGGGAGTTTGC-3′). By these primers, a segment of HBV DNA spanning 944 nucleotide from 1604 to 2547, which comprises the entire precore and core region, was amplified by the polymerase chain reaction (PCR). These primers were synthesized by the phosphoramidite method. The PCR reaction was conducted in a 100*μ*l mixture containing 10*μ*l of the specimen DNA, 2.5 U of Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA), 400 mM of each dNTP, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl~2~ and 0.5*μ* M of each primer. The reaction mixture, except each primer, was preheated to 85°C and each primer was added to the mixture. The amplification reaction was cycled 35 times with 30 seconds of denaturation at 94°C, 30 seconds of annealing at 55°C, and 1 minute of extension at 72°C in a programmable thermal cycler (GeneAmp 9600, Perkin-Elmer/Cetus).

We carefully followed the recommendation of Kwok and Higuchi to avoid false-positive PCR^[@b18-kjim-10-2-87-2]^.

For direct sequencing of a portion of HBV DNA, each PCR product was eluted from the 0.8% agarose gel slice, excised under the indirect ultraviolet visualization, by using the Magic™ PCR Prep kit (Promega, Madison, WI, USA).

We prepared several sequencing primers to sequence bi-directionally: sense primers, P1 (nt 1741--1758, 5′-GGGAGGAGATTAGGTTAA-3′), P2 (nt 1843--1867, 5′-CATGTTCATGTCCTACTGTTCA-3′), P3 (nt 2047--2071, 5′-CTCATCATACAGCACTCAGGCAAGC-3′), P4 (nt 2292--2310, 5′-TACAGACCACCAAATGCCC-3′); antisense primers, M1 (nt 2472--2497, 5′-AGAATAAAGCCCAGTAAAGTTTCCC-3′), M2 (nt 2287--2310, 5′-GGGCATTTGGTGGTCTGTA-3′), M3 (nt 2114--2138, 5′-TGCTGGGTCTTCCAAATTACTTCCC-3′), M4 (nt 2047--2067, 5′-GCCTGAGTGCT GTATGATGAG-3′), M5 (nt 1910--1934, 5′-AGAAGCTCCAAATTCTTTATACG-3′). Each sequencing primer was radiolabeled with *γ*-^32^P-ATP using T4 polynucleotide kinase. From 40 to 100 fmol of purified PCR product and 1.5 pmol of each radiolabeled primer was used for cycle sequencing reaction^[@b19-kjim-10-2-87-2]^ using thermostable DNA polymerase (fmol™ sequencing system, Promega, Madison, WI, USA). The reaction products were analyzed on a 8% sequencing gel. For ease of detection of mutations, we used a nontraditional gel-loading format^[@b20-kjim-10-2-87-2]^ in which all G-terminated reaction products from a single primer are loaded side-by-side, followed by all the A-terminated reactions, etc. (GGGGAAAATTTTCCCC) ([Fig. 1](#f1-kjim-10-2-87-2){ref-type="fig"}). This format allowed mutations to be detected by virtue of the differences in the banding patterns, rather than by reading each sequence and comparing it to the known sequence. HBsAg subtypes in the fifteen patients were all adr. When four previously reported amino acid residues of the HBV with adr subtype^[@b17-kjim-10-2-87-2],[@b21-kjim-10-2-87-2]--[@b23-kjim-10-2-87-2]^ were aligned, the sequences showed well conserved amino acid residues of core peptides and the only difference was in the codon 169. Since, in all patients, the deduced amino acid residue in the codon 169 was consistent with all 3 sequences reported in Japan, we used that sequence as a prototype HBV.

4.. Statistical Analysis
------------------------

Fisher's exact test and Mann-Whitney U test were used for statistical analysis.

RESULTS
=======

1.. Nucleotide Sequence and Deduced Amino Acid Residue of Core Gene
-------------------------------------------------------------------

The entire nucleotide sequence of the core gene of HBV was obtained in all 15 patients. A total of 181 nucleotide substitutions were found in the HBV core gene from the 15 CH-B patients (101 from 8 CPH patients, 80 from 7 CAH patients). Twenty-three of them were missense mutations and 158 were silent. The substitution rate at each nucleotide position was 2.198×10^−2^ (2.230×10^−2^ for CPH patients and 2.082×10^−2^ for CAH patients), and the occurrence of missense mutation at each codon was 0.838×10^−2^ (0.683×10^−2^ for CPH patients and 1.015×10^−2^ for CAH patients); therefore, the nucleotide and amino acid substitution rates were not significantly different between the two groups (p\>0.05). Six of the 8 CPH (75.0%) and six of the 7 CAH (87.1%) patients had at least one missense mutation in the HBV core gene ([Table 1](#t1-kjim-10-2-87-2){ref-type="table"}).

2.. Missense Mutation Clustering in Different Regions of HBV Core Gene
----------------------------------------------------------------------

Two mutational hot spots were found in codons 21--34 (MHS1) and codons 85--100 (MHS2) in the deduced amino acid alignment of the HBV core gene ([Fig. 2](#f2-kjim-10-2-87-2){ref-type="fig"}). The alteration rate of amino acid residue in these regions were 2.857×10^−2^ and 5.000×10^−2^, respectively. Of 8 CPH patients, 5 showed missense mutations only in MHS2. In comparison, of 7 CAH patients, 3 showed them both in MHS1 and MHS2, 1 only in MHS1 and 1 only in MHS2; thus, missense mutation in MHS1 was exclusively found in patients with CAH.

DISCUSSION
==========

Viruses yield a high proportion of mutants on continuous replication in the absence of known mutagens. These spontaneous mutations accumulate in the genomes of the viruses, resulting in the variation of phenotypes ("viral quasispecies")^[@b24-kjim-10-2-87-2],[@b25-kjim-10-2-87-2]^, which subject the virus to selective pressure during evolution. When no variants with higher fitness are generated, the consensus (average) sequence of the population remains unchanged. By contrast, changes in environment of selective pressures lead to the emergence of variants with higher fitness for the new environment, which undergo further rounds of replication and become progeny virions. Such immune selection occurs not only with antibodies, but also with cytotoxic T cells^[@b26-kjim-10-2-87-2],[@b27-kjim-10-2-87-2]^.

The in vivo mutation rate of hepadna virus was estimated to be lower than that of RNA viruses and higher than that of DNA viruses^[@b28-kjim-10-2-87-2]^. Presumably, such a high frequency of mutation is a result of HBV replication via reverse transcription of a RNA intermediate^[@b29-kjim-10-2-87-2]^. But there are constraints on the ability of HBV to accept mutations without becoming non-viable. The genome is only about 3200 bases long, the smallest of any DNA virus that infects man, and all the genetic material codes for proteins with the regulatory elements being found within these coding regions^[@b30-kjim-10-2-87-2]^.

It has been suggested that the core peptide is an immunological target of CTL in HBV infection^[@b11-kjim-10-2-87-2]^. Recent studies revealed that the endogenously processed viral peptides bound with the class 1 major histocompatibility complex (MHC) were recognized by CTL^[@b12-kjim-10-2-87-2]^. Indeed, the core gene of HBeAg-positive Japanese and Chinese patients with chronic hepatitis showed clustered amino acid substitutions or deletions^[@b14-kjim-10-2-87-2],[@b15-kjim-10-2-87-2]^, probably as a result of immune pressure from CTL. However, the mutation clustering regions reported from different countries showed divergence. Mutation clusterings were found between amino acids 80 and 110 in Japanese patients^[@b14-kjim-10-2-87-2]^, whereas, in Chinese, those were found in codon 48--60, 84--101 and 147--155^[@b15-kjim-10-2-87-2]^. In the present study, we found that missense mutations in core gene of Korean patients with chronic active hepatitis were clustered in codon 21--34 and 85--100; therefore, we confirmed such an ethnic diversity of major regions of mutation clustering. It has not been defined what causes this diversity. A recent study of the amino acid sequences eluted from MHC molecules revealed that class I MHC had allele-specific binding motifs^[@b31-kjim-10-2-87-2]^. Thus, the major regions for mutation clustering could be different among chronic HBV-infected patients from different ethnic groups because of differing distributions of HLA antigens^[@b32-kjim-10-2-87-2]--[@b34-kjim-10-2-87-2]^ and the varying amino acids sequences among HBV subtypes.

It is not known why there are differences in the severity of liver disease among different HBV-infected individuals. In the present study, the number of missense mutations were not significantly different between the patients with CPH and CAH. Similarly, the occurrences of missense mutations in the MHS2 (codon 85--100), which is consistent with the MCR1 reported by Ehata et al.^[@b14-kjim-10-2-87-2]^, were not different between the two groups. In contrast, a mutation clustering region of 14 amino acid residues (MHS1; core codon from 21 to 34) was found in four of 7 patients (57.1%) with CAH, but in none of 8 (0.0%) CPH patients, suggesting that it is not the mutations in the MHS2 but those in the MHS1 that are more related to severity of CH-B. Actually, the mutation clustering region corresponding to MHS1 was also shown by Ehata et al.^[@b35-kjim-10-2-87-2]^ in four of seven (57.1%) Japanese patients with severe exacerbation of CH-B or fulminant hepatitis due to adr subtype of HBV.

Recently, Bertoletti et al. reported that the optimal amino acid sequence recognized by CTL from acute hepatitis B patients was a 10 mer (residues 18 to 27) containing the predicted peptide-binding motif for HLA-A2 and that this peptide could stimulate CTL that was able to recognize endogenously synthesized hepatitis B core antigen^[@b36-kjim-10-2-87-2]^. Interestingly, the MHS1 overlaps with the minimal optimal cytotoxic T-cell epitope. The missense mutations in MHS1 may result from the immune selection by CTL since the most frequent HLA-A phenotype in Korea is A2 (phenotype frequency=0.5392)^[@b32-kjim-10-2-87-2]^. However, it was also reported that patients with chronic HBV infection failed to mount an efficient CTL response to a synthetic HBV core antigen residue 11 to 27^[@b37-kjim-10-2-87-2]^. Furthermore, it is now clear that the different disease induced by HBV are caused by complex interaction between a particular viral genotype and the "quality" and perhaps "quantity" of the host's immune response to that viral agent. Thus, to clarify the role of missense mutations in MHS1 in the pathogenesis of more severe CH-B, a longitudinal study with the use of sequential serum samples rather than a cross sectional study is warranted.
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###### 

Clinical and Laboratory Data on 15 Patients with Chronic Hepatitis B

  No.   Age   Sex   HBeAg   Anti-HBe   Precore stop codon   Core mutation (missense)   Pathology
  ----- ----- ----- ------- ---------- -------------------- -------------------------- ------------
  CP1   22    M     \+      −          −                    −                          CPH
  CP2   21    M     \+      −          −                    \+                         CPH
  CP3   21    M     \+      −          −                    \+                         CPH
  CP4   21    M     \+      −          −                    \+                         CPH
  CP5   19    M     −       \+         −                    \+                         CPH
  CP6   20    M     \+      −          −                    \+                         CPH
  CP7   30    M     \+      −          −                    \+                         CPH
  CP8   20    M     \+      −          −                    −                          CPH
  CA1   55    M     \+      −          −                    −                          CAH
  CA2   54    M     \+      −          −                    \+                         CAH
  CA3   31    M     \+      −          −                    \+                         CAH
  CA4   19    M     \+      −          −                    \+                         CAH
  CA5   21    M     \+      −          −                    \+                         CAH
  CA6   57    F     \+      −          −                    \+                         CAH
  CA7   36    M     \+      −          −                    \+                         LC, active
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